Obinutuzumab in Combination With Lenalidomide in Relapsed or Refractory Follicular Lymphoma in Real World Study

NCT05846763 · clinicaltrials.gov ↗
RECRUITING
Status
50
Enrollment
OTHER
Sponsor class

Conditions

Sponsor

Institute of Hematology & Blood Diseases Hospital, China